🇺🇸 FDA
Patent

US 11384076

Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors

granted A61PA61P35/02A61P35/04

Quick answer

US patent 11384076 (Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors) held by Universität Regensburg expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Universität Regensburg
Grant date
Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P35/02, A61P35/04